DOCSLIB.ORG

US 2019 / 0040000 A1 Narayanan Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
US 2019 / 0040000 A1 Narayanan Et Al US 20190040000A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 / 0040000 A1 Narayanan et al. (43 ) Pub . Date : Feb . 7 , 2019 ( 54 ) SELECTIVE ANDROGEN RECEPTOR (60 ) Provisional application No .62 / 220 ,094 , filed on Sep . DEGRADER (SARD ) LIGANDS AND 17 , 2015 , provisional application No . 62 /150 , 768 , METHODS OF USE THEREOF filed on Apr. 21 , 2015 . ( 71 ) Applicants :GTx , Inc ., Memphis , TN (US ) ; University of Tennessee Research Publication Classification Foundation , Knoxville , TN (US ) (51 ) Int. Cl. C07C 237 / 20 ( 2006 .01 ) ( 72 ) Inventors : Ramesh Narayanan , Cordova , TN A61P 25 / 00 ( 2006 .01 ) ( US ) ; Duane D . MILLER , Collierville , A61P 5 / 28 TN (US ) ; Thamarai PONNUSAMY , (2006 .01 ) Memphis , TN (US ) ; Dong - Jin A61P 35 / 00 ( 2006 .01 ) HWANG , Arlington , TN (US ) ; Charles (52 ) U . S . CI. B . DUKE , Memphis , TN (US ) ; CPC .. C07C 237/ 20 ( 2013 .01 ) ; A61P 25 /00 Christopher C . COSS , Upper ( 2018 .01 ) ; A61P 35 / 00 ( 2018 .01 ) ; A61P 5 /28 Arlington , OH (US ) ; Amanda JONES , ( 2018 .01 ) Silver Spring , MI (US ) ; James T . DALTON , Ann Arbor , MI (US ) ( 57 ) ABSTRACT (21 ) Appl. No. : 16 /153 , 193 This invention provides novel 3 - amino propanamide selec tive androgen receptor degrader (SARD ) compounds , phar ( 22 ) Filed : Oct . 5 , 2018 maceutical compositions and uses thereof in treating pros tate cancer , advanced prostate cancer, castration resistant Related U . S . Application Data prostate cancer , androgenic alopecia or other 5 hyperandro (63 ) Continuation of application No . 15 / 830 , 688, filed on genic dermal diseases, Kennedy ' s disease , amyotrophic lat Dec . 4 , 2017 , now Pat. No . 10 , 093 ,613 , which is a eral sclerosis ( ALS ) , and uterine fibroids , and to methods for continuation - in - part of application No . 15 /331 , 751 , reducing the levels of androgen receptor- full length (AR filed on Oct. 21 , 2016 , now Pat . No. 9 , 834 ,507 , which FL ) including pathogenic or resistance mutations, AR - splice is a continuation - in -part of application No . 15/ 135 , variants (AR -SV ) , and pathogenic polyglutamine (polyQ ) 151, filed on Apr. 21, 2016 , now Pat. No . 9 ,815 ,776 . polymorphisms of AR in a subject . 0) , in It 36 pix CMH 37 . Coronad 1 AS RU * 10 300 301x } 10 .000 ACT Compoudd 17 4- 0 . 1 011 83981 OM 1418 1010 10 , 000 + + + + + + + + + + + + + + + + + + + Cxoplonost 17 var 791 let Actia 1 . Car ws Betis WOMMV: 00 AR itx Buzdo TOM Corsyon sa Lesio AR coix Patent Application Publication Feb . 7 , 2019 Sheet 1 of 16 US 2019 /0040000 A1 0 . 3 WX3881 1933 . Crond 37 . * * * * ! ! ! ! ! ! ! ! ! Compound! ! ! ! ! ! ! ! 17! . - . - . 12WXUA Compound 1 ? . .. cececececs Compound 17 Vet Activ List OMMOV3300 { has{ ttis TOM Csapjunkl. 14 AR Figure 1 Patent Application Publication Feb . 7 , 2019 Sheet 2 of 16 US 2019 /0040000 A1 0 . 1 RW R1881 0 . 1 W R1881 M . 1 10 100 1000 10000 Copa 17 Figure 2A 0 .35 0 . 3 0 .25 $ 0 . 2 50 .15 0 .13 0 .05 100010000 1001000 10000 1001000 10000 Enzalutamide ARN - 509 Compound 17 Figure 28 Patent Application Publication Feb . 7 , 2019 Sheet 3 of 16 US 2019 /0040000 A1 ter *777777 w tiettttt 1 w pt on ** 292 st*** * * * MEDTA14 100100010000 -110102103104. 0.1MR18811AM TE WWW wwwWE metai0.1mmR1881 10 . 1 . AND . - MASC-19 ARIActin Cmpd-17 ASC-J9 ARN-509 Figure3 th th stitih htpotwih !home WWWIN 100100010000 0.1OMR18810.1OMR1881 aMcmpd17-110102103104. in0.10MR1881 FUL 110 nik pe . 0.50 00.0 Actin/ AR AM AR-FL. AR-V7 ARFL AR-FL V7-AR Patent Application Publication Feb . 7 , 2019 Sheet 4 of 16 US 2019 /0040000 A1 B ( continued ) 24 country MA*** 4440+AHH 14*** AR/Actin tott * * L skatteretter **** * Westershid444Ah 444 MARA with VA . DM ARN 500 1 10 104 104 104 . - 1 10 102 103 104 Cmpd 14 MDV - 3100 AR AR- - 5V SV -- - - - - - - Actin - Figure 3 ( continued ) Patent Application Publication Feb . 7 , 2019 Sheet 5 of 16 US 2019 /0040000 A1 #{R}AB CITU Cuss BRS 17 : 31 WWW * * * * * K3887 No cross - reactivity to ER No cross- reactivity to PR 3 : Cusd 17 Cud 17 hirsill 12 24 48 72 ERO Quia Figure 4 Patent Application Publication Feb . 7 , 2019 Sheet 6 of 16 US 2019 /0040000 A1 Prostate Compound 17 Compound 14 Prostate(mg/gb.wt) 20 mgs BID 20 mgs BID 13 UM * hr 320M * hr SV Compound 17 Compound 14 20 mys BID 20 mgs BID (IM*q7/8u)A'S 13 Mihr 320M * hr Figure 5 Patent Application Publication Feb . 7 , 2019 Sheet 7 of 16 US 2019 /0040000 A1 3. 09 2. 8 RLU 2. 446 GRS * 1. 4 * 1 . 2 Compound 17 + 0 . 1 nM Dex 10 - 5 18 - 4 le - 3 10 - 2 10 - 1 10 - 0 10 + 1 10 + 2 14 + 3 10 + 4 1e + 5 nM (Dexamethasone ) RLU CMR om Compound 17 + 0 . 1 nM Ald 0 . 8mm 1e - 5 18 - 4 1e - 3 10 - 2 1 - 1 1e + 0 1e + 1 1e + 2 1e + 3 le + 4 18 + 5 NM (Aldesterone ) PR . 0. 2 . 1e - 5 10 -4 10 - 3 10 -2 10 - 1 10 + 0 10 + 1 18 + 2 1e + 3 14 + 4 10 + 5 nM (Progesterone ) Figure 6 Patent Application Publication Feb . 7 , 2019 Sheet 8 of 16 US 2019 /0040000 A1 RNA Poll (PSA Esku. KNA PII (PSA Pr033 . } . DIA Pestras C . KNA Poil (FKBP ARE ) RNA Polli ( IMPRSS ? ARE ) . POMPIR . RIN1051 C . 17 Bic · Cmd 1 . Bie M YYYYYYYYYYYYYYYYYYYYYYY R1881 RI881 01RM 11881 M1881 - 4. Comund 17 UUUUUUUUUUUUUUUUUUUUUUUUUU Lower magnificatios .TR Fligbes magnification : Beus Figure 7 Patent Application Publication Feb . 7 , 2019 Sheet 9 of 16 US 2019 /0040000 A1 ve inimiiiiiiiiiiiiiiiiiiiiiiiiiiiii Melalui SSSSSSSSS leteleleelteleteleletelteleletele log{ Cmpd 17 ) Figure 8 Patent Application Publication Feb . 7 , 2019 Sheet 10 of 16 US 2019 /0040000 A1 R1881 Comp 49 OM . 100 1000 10000 AR Actin Figure 9 AR Comp 49 AR - V7 ActinoNO Figure 10 Patent Application Publication Feb . 7 , 2019 Sheet 11 of 16 US 2019 /0040000 A1 Figure 11A Enobosarm Cmpd 17 AFI+ TMAO + E mummaande * * AELF AFI + TMAO + 17 **** * Relativefluorescence singumandaimme memandanganmaahanmuudanten ** ** * na kriminiminimimininingninimiminiminiminigaminiminiminiminingin wwwind AFI AF1 AFI AF1 + TMAO Figure 11B AR AF - 1 AR AF - 1 + 1 M 17 nommaitmomentumuntammentmomenttradumandangenun ARAF - 1 + 10 UM 17 FluorescenceIntensity AR AF- 1 + 15 UM 17 mantannnnnnnnnnnnnnnndengan 2x (307nm) Wavelength (nm ) AFluorescence Concentration Cpd (UM ) Patent Application Publication Feb . 7 , 2019 Sheet 12 of 16 US 2019 /0040000 A1 Sefa AFTAF1 loaded biosesors COMPOUND 17 wwambwandownloadinandorondombombomman ERD14 reference biosensors within Biocytin reference biosensors momentan 1700 1800 1900 2000 2100 2200 Time (sec ) Figure 12 Patent Application Publication Feb . 7 , 2019 Sheet 13 of 16 US 2019 /0040000 A1 150 . 100 RLU - 17 (48 , 44 nM ) 50 - A Enza ( 464 .82 nM ) - 14 12 10 8 6 M ( log ) Figure 13A Patent Application Publication Feb . 7 , 2019 Sheet 14 of 16 US 2019 /0040000 A1 1504 100 RLU + AR - - W741L - AR * T877A -AR - 14 - 12 - 10 - 8 M (log ) 17 Figure 13B RLU(%) AR - - GR * MR - 12 - 10 - - 6 -50 M ( log ) 17 Figure 13C FKBPS/GAPDH(Fold) Enza Figure 13D Patent Application Publication Feb . 7 , 2019 Sheet 15 of 16 US 2019 /0040000 A1 Figure 14A 0 . 1 nM R1881 W Figure 148 Gene/GAPDH(Fold) FKBP5 . AR 0 .0 + - 14 - 12 - 10 - 8 - 6 - 4 M ( log ) 17 Figure 15 Patent Application Publication Feb . 7 , 2019 Sheet 16 of 16 US 2019 /0040000 A1 AR (PSA Enhancer ) AR/Input Vehicle R1881 17+R1881 Bical+R1881 Figure 16A RNA Pol II ( PSA Promoter ) PolIl/Input Vehicle R1881 17+R1881 Bical+R1881 Figure 16B US 2019 /0040000 A1 Feb . 7 , 2019 SELECTIVE ANDROGEN RECEPTOR [0006 ] A critical barrier to progress in treating CRPC is DEGRADER (SARD ) LIGANDS AND that AR signaling inhibitors such as enzalutamide, bicalu METHODS OF USE THEREOF tamide , and abiraterone , acting through the LBD , fail to inhibit growth driven by the N - terminal domain (NTD ) CROSS REFERENCE TO RELATED dependent constitutively active AR - SV such as AR - V7, the APPLICATIONS most prominent AR - SV . Recent high - impact clinical trials with enzalutamide and abiraterone in CRPC patients dem [ 0001 ] This Application is a Continuation -in - Part applica onstrated that just 13 . 9 % of AR - V7 - positive patients among tion of U . S . patent application Ser . No . 15 /830 ,688 , filed on 202 patients starting treatment with enzalutamide (Xtandi ) Dec . 4 , 2017 , which is a Continuation - in - Part application of or abiraterone acetate ( Zytiga ) had PSA responses to either U . S . patent application Ser. No . 15 /331 , 751, filed on Oct. 21 , of the treatments ( Antonarakis E S , Lu C , Luber E , et al. J . 2016 , now U . S . Pat . No. 9 ,834 , 507, which is a Continuation Clin . Oncol . 2017 April 6 . doi: 25 10 . 1200 /X0 . 2016 . 70 . in -Part application of U . S . patent application Ser. No . 1961) , indicating the requirement for next generation AR 15 / 135 , 151 , filed on Apr. 21 , 2016 , now U . S . Pat . No. antagonists that target AR - SVs. In addition , a significant 9 , 815 , 776 , which claims the benefit of U . S . Provisional number of CRPC patients are becoming refractory to abi Application Ser. No . 62 /220 , 094 , filed on Sep . 17 , 2015 , and raterone or enzalutamide , emphasizing the need for next U . S . Provisional Application Ser . No . 62 / 150 , 768 , filed on generation AR antagonists . Apr. 21 , 2015 , which are incorporated in their entirety herein [0007 ] Current evidences demonstrate that CRPC growth by reference . is dependent on constitutively active AR including AR -SV ' s that lack the LBD such as AR - V7 and therefore cannot be FIELD OF THE INVENTION inhibited by conventional antagonists . AR inhibition and [0002 ] This invention is directed to 3 - amino -propanamide degradation through binding to a domain that is distinct from selective androgen receptor degrader (SARD ) compounds, the AR LBD provides alternate strategies to manage CRPC .
Load more

Recommended publications
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • ( 12 ) United States Patent
    US010314797B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 314 ,797 B2 Narayanan et al. ( 45 ) Date of Patent : * Jun . 11, 2019 ( 54 ) SELECTIVE ANDROGEN RECEPTOR ( 56 ) References Cited DEGRADER (SARD ) LIGANDS AND METHODS OF USE THEREOF U . S . PATENT DOCUMENTS 5 ,480 ,656 A 1 / 1996 Okada et al . (71 ) Applicant: University of Tennessee Research 5 ,575 , 987 A 11/ 1996 Kamei et al . Foundation , Knoxville , TN (US ) 5 ,631 , 020 A 5 / 1997 Okada et al. 5 , 643 ,607 A 7 / 1997 Okada et al. 5 ,716 ,640 A 2 / 1998 Kamei et al. ( 72 ) Inventors : Ramesh Narayanan , Cordova , TN 5 , 814 ,342 A 9 / 1998 Okada et al . (US ) ; Duane D . Miller , Collierville , 6 ,036 , 976 A 3 / 2000 Takechi et al . TN (US ) ; Thamarai Ponnusamy , 7 , 118 , 552 B2 10 / 2006 Shaw et al . Memphis , TN (US ); Dong - Jin Hwang, 7 , 220 , 247 B25 / 2007 Shaw et al . 7 ,500 , 964 B23 / 2009 Shaw et al . Arlington , TN (US ) ; Yali He, 9 ,815 , 776 B2 * 11 / 2017 Narayanan . .. .. C07C 255 /60 Germantown , TN (US ) 9 , 834 , 507 B2 * 12 / 2017 Narayanan . .. .. .. C07C 255 /60 2005 /0101657 A1 5 /2005 Furuya et al . (73 ) Assignee : University of Tennessee Research 2007 /0265290 A1 11/ 2007 Dalton et al . 2010 /0227846 AL 9 /2010 Ito et al. Foundation , Knoxville , TN ( US ) 2014 / 0018433 A11 / 2014 Dalton et al . ( * ) Notice : Subject to any disclaimer , the term of this 2018 /0118663 A1 * 5 / 2018 Narayanan . C07C 237/ 20 patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U . S .
    [Show full text]
  • 7.Alpha.-Methyl 19-Nortestosterone
    Europäisches Patentamt *EP001087986B1* (19) European Patent Office Office européen des brevets (11) EP 1 087 986 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C07J 1/00, A61K 31/565 of the grant of the patent: 10.04.2002 Bulletin 2002/15 (86) International application number: PCT/EP99/04102 (21) Application number: 99929208.9 (87) International publication number: (22) Date of filing: 14.06.1999 WO 99/67271 (29.12.1999 Gazette 1999/52) (54) 7.ALPHA.-METHYL 19-NORTESTOSTERONE UNDECANOATE WITH ANDROGENIC ACTIVITY 7.ALPHA.-METHYL 19-NORTESTOSTERON UNDECANOAT MIT ANDROGENISCHER AKTIVITÄT DERIVE DE TESTOSTERONE (84) Designated Contracting States: (56) References cited: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU US-A- 5 342 834 MC NL PT SE • CHEMICAL ABSTRACTS, vol. 127, no. 18, 3 (30) Priority: 19.06.1998 EP 98202052 November 1997 (1997-11-03) Columbus, Ohio, US; abstract no. 243354, KUMAR N ET AL: (43) Date of publication of application: "Pharmacokinetics of 04.04.2001 Bulletin 2001/14 7.alpha.-methyl-19-nortestosterone in men and cynomolgus monkeys" page 89; column 2; (73) Proprietor: Akzo Nobel N.V. XP002082919 & J. ANDROL., vol. 18, no. 4, 1997, 6824 BM Arnhem (NL) pages 352-358, • CHAUDRY M A Q ET AL: "Hansch analysis of the (72) Inventors: anabolic activities of some nandrolone esters" • LEYSEN, Dirk JOURNAL OF MEDICINAL CHEMISTRY., vol. 17, B-3920 Lommel (BE) no. 2, February 1974 (1974-02), pages 157-161, • VAN DER VOORT, Hendrikus, Adrianus, XP002082918 WASHINGTON US Antonius • CHEMICAL ABSTRACTS, vol.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • WO 2012/148570 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148570 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61L 27/14 (2006.01) A61P 17/02 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, C08L 101/16 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, PCT/US20 12/027464 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 2 March 2012 (02.03.2012) SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 13/093,479 25 April 201 1 (25.04.201 1) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant (for all designated States except US): DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, WARSAW ORTHOPEDIC, INC.
    [Show full text]
  • Gas Chromatographic/Mass Spectrometric Analysis of 19-Nortestosterone Urinary Metabolites in Cattle Etienne Benoit, J.L
    Gas chromatographic/mass spectrometric analysis of 19-nortestosterone urinary metabolites in cattle Etienne Benoit, J.L. Guyot, D. Courtot, P. Delatour To cite this version: Etienne Benoit, J.L. Guyot, D. Courtot, P. Delatour. Gas chromatographic/mass spectrometric anal- ysis of 19-nortestosterone urinary metabolites in cattle. Annales de Recherches Vétérinaires, INRA Editions, 1989, 20 (4), pp.485-491. hal-00901913 HAL Id: hal-00901913 https://hal.archives-ouvertes.fr/hal-00901913 Submitted on 1 Jan 1989 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Original article Gas chromatographic/mass spectrometric analysis of 19-nortestosterone urinary metabolites in cattle E. Benoît J.L. Guyot D. Courtot P. Delatour 1 INRA, Laboratoire No. 54i89, service de biochimie, Ecole Nationale Vétérinaire de Lyon, BP 31, 69752 Charbonnières Cedex; 2 INRA-ENVL, laboratoire de recherches sur le cheval de sport, Ecole Nationale Vétérinaire de Lyon, BP 31, 69752 Charbonnières Cedex, France (received 31 May 1988, accepted 18 January 1989) Summary ― Gas chromatographic and mass spectrometric method is used to confirm the administration of 19-nortestosterone to cattle. The most abundant metabolites detected were 19- norepitestosterone and 5a-oestrane-3p,17a-diol.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0078091 A1 Hubler Et Al
    US 20070078091A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0078091 A1 Hubler et al. (43) Pub. Date: Apr. 5, 2007 (54) PHARMACEUTICAL COMBINATIONS FOR (30) Foreign Application Priority Data COMPENSATING FORATESTOSTERONE DEFICIENCY IN MEN WHILE Sep. 6, 1998 (DE)..................................... 198 2.55918 SMULTANEOUSLY PROTECTING THE PROSTATE Publication Classification (76) Inventors: Doris Hubler, Schmieden (DE): (51) Int. Cl. Michael Oettel, Jena (DE); Lothar A6II 38/09 (2007.01) Sobek, Jena (DE); Walter Elger, Berlin A 6LX 3/57 (2007.01) (DE); Abdul-Abbas Al-Mudhaffar, A6II 3/56 (2006.01) Jena (DE) A 6LX 3/59 (2007.01) A 6LX 3/57 (2007.01) A61K 31/4709 (2007.01) Correspondence Address: A6II 3L/38 (2007.01) MILLEN, WHITE, ZELANO & BRANGAN, (52) U.S. Cl. ............................ 514/15: 514/171; 514/170; P.C. 514/651; 514/252.16; 514/252.17; 22OO CLARENDON BLVD. 514/3O8 SUTE 14OO ARLINGTON, VA 22201 (US) (57) ABSTRACT This invention relates to pharmaceutical combinations for (21) Appl. No.: 11/517,301 compensating for an absolute and relative testosterone defi ciency in men with simultaneous prophylaxis for the devel opment of a benign prostatic hyperplasia (BPH) or prostate (22) Filed: Sep. 8, 2006 cancer. The combinations according to the invention contain a natural or synthetic androgen in combination with a Related U.S. Application Data gestagen, an antigestagen, an antiestrogen, a GnRH analog. a testosterone-5C.-reductase inhibitor, an O-andreno-receptor (63) Continuation of application No. 09/719,221, filed on blocker or a phosphodiesterase inhibitor. In comparison to Feb. 16, 2001, filed as 371 of international application the combinations according to the invention, any active No.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,315,447 B2 Gjorstrup Et Al
    USOO9315447B2 (12) United States Patent (10) Patent No.: US 9,315,447 B2 Gjorstrup et al. (45) Date of Patent: *Apr. 19, 2016 (54) COMPOSITIONS AND METHODS FOR THE (52) U.S. Cl. TREATMENT OF INFLAMMATION CPC ............. C07C 69/732 (2013.01); C07C 69/734 (2013.01) (71) Applicant: A.T. Resolve Sarl, St-Legier (CH) (58) Field of Classification Search (72) Inventors: Per Gjorstrup, Cambridge, MA (US); CPC ............................ C07C 69/732; C07C 69/734 C. Eric SchwartZ, Wakefield, MA (US USPC ............................................................ 514f63 . Lric SchwartZ, eleld, (US) See application file for complete search history. (73) Assignee: A.T. RESOLVE SARL, Lausanne (CH) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this U.S. PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. 4,172,896 A 10/1979 Uno et al. 4,346,227 A 8, 1982 Terahara et al. This patent is Subject to a terminal dis- 4,444,784. A 4, 1984 Hoffman et al. claimer. 4,681,893 A 7, 1987 Roth 5,354,772 A 10, 1994 Kathawala (21) Appl. No.: 14/207,342 (Continued) (22) Filed: Mar 12, 2014 FOREIGN PATENT DOCUMENTS (65) Prior Publication Data WO 2006,105.058 A2 10, 2006 WO 2009/038671 3, 2009 US 2014/0275,247 A1 Sep. 18, 2014 (Continued) Related U.S. Application Data OTHER PUBLICATIONS (63) Continuation of application No. 13/264,155, filed as & 8 s application No. PCT/US2010/030812 on Apr. 13, Becker et al., “Hydrolyse von Carbonsaurederivaten . Organikum, 2010, now Pat No.
    [Show full text]
  • PRODUCTS LIST MNC Print Date : 13.Sep.2017
    PRODUCTS LIST MNC Print Date : 13.Sep.2017 S# Item Name PackSize Origin Formulation / Specification Manufacturer FOB (USD) 1 ABOCAIN INJECTION 0.5% 5ML 5MLx5'S Pakistan BUPIVACAINE HCI 5MG 0.5% ABBOTT LABORATORIES (PAK) 2.60 (BUPIVACAINE HEAVY) LTD 2 ABOCAIN SPINAL INJECTION 7.5MG 2ML 5MLx5'S Pakistan BUPIVACAINE HCI 5MG 7.5MG ABBOTT LABORATORIES (PAK) 2.63 LTD 3 ACENAC TABLET 100 MG 30'S Pakistan Contain's : ACECLOFENAC S.J&G PVT LTD 1.76 100MG 4 ACNE AID BAR 65GM Pakistan MEDICATED SOAP RECKITT BENCKISER 1.51 5 ACTIDIL SYRUP 60ML Pakistan TRIPROLIDINE (HCL) 2MG/5ML GLAXO SMITHKLINE 0.17 6 ACYCLOVIR 500MG INJECTION 5MLx5'S Pakistan ACYCLOVIR 500MG ABBOTT LABORATORIES (PAK) 9.54 LTD 7 ADALAT RETARD TABLET 3X10'S Pakistan CONTAINS :NIFEDIPINE 20mg BAYER SCHERING PHARMA 1.67 USP 8 ADVANTAN CREAM 10GM Pakistan CONTENT'S: BAYER PAKISTAN ( PVT.) LTD. 1.99 METHYLPREDNISOLONE ACEPONATE 0.1% 9 AEROLIN EVOHALER INHALER 100MCG 1'S Pakistan - GLAXO SMITHKLINE 1.96 10 AGAPURIN RETARD TABLET 400MG 20'S Pakistan CONTENT'S: PENTOXIFYLINE NEO MEDIX PHARMACEUTICA. 3.97 400MG PAKISTAN 11 AGGRASTAT .25MG INJ 50ML Pakistan CONTENT 's: TIROFIBAN ATCO LABORATORIES 161.08 250MCG 50MLINJ. 12 ALDACTONE 100 MG TABLET 10's Pakistan Each tab contain's: SEARLE PAKISTAN LTD. 0.85 SPIRONOLACTONE 100mg 13 ALDACTONE -A TAB 25 MG 100'S Pakistan CONTENT 's : SPIRO SEARLE PAKISTAN LTD. 1.72 NOLACTONE 25MG 14 ALDOMET TABLET 250 MG 100'S Pakistan CONTAINS :METHYLDOPA U.S.P OBS PHARMA 6.24 250MG 15 AMARYL TABLET 1MG (GLIMEPIRIDE) 3X10'S Pakistan GLIMEPIRIDE 1MG SANOFI AVENTIS 2.30 16 AMARYL TABLET 2MG (GLIMEPIRIDE) 3X10'S Pakistan CONTENTS: GLIMEPIRIDE 2MG SANOFI AVENTIS 4.56 17 AMARYL TABLET 3MG (GLIMEPIRIDE) 3X10'S Pakistan CONTENTS: GLIMEPIRIDE 3MG SANOFI AVENTIS 6.85 18 AMARYL TABLET 4MG (GLIMEPIRIDE) 3X10'S Pakistan CONTENTS: GLIMEPIRIDE 2MG SANOFI AVENTIS 9.12 19 AMINOLEBAN 20% 500ML INFUSION 500ML Pakistan PER 500ML SOLN: OTSUKA PAISTAN 5.48 L-THREONINE J.P...4.5GM, L-SERINE U.S.P ...5.0GM, L-PROLINE U.S.P...8.0GM, L-CYSTEINE HCL.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0271275 A1 Biggs Et Al
    US 20120271275A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0271275 A1 Biggs et al. (43) Pub. Date: Oct. 25, 2012 (54) MEDICAL DEVICES AND METHODS Publication Classification COMPRISING AN ANABOLICAGENT FOR (51) Int. Cl WOUND HEALING A6II 3/58 (2006.01) A6M 5/42 (2006.01) (75) Inventors: Danielle L. Biggs, Collierville, TN A6IP 7/02 (2006.01) 5147 (US); Jared T. Wilsey, Memphis, (52) U.S. Cl. ......................................... 604/506; 514/176 TN (US) (57) ABSTRACT Improved medical devices and methods are provided com (73) Assignee: WARSAW ORTHOPEDIC, INC., prising an anabolic agent for wound healing. These improved Warsaw, IN (US) medical devices and methods can enhance wound healing in wounds from cuts, abrasions, lesions, burns including Sun burn, Surgical incisions, pressure ulcers, diabetic ulcers, trau (21) Appl. No.: 13/093,479 matic wounds, or other injuries or maladies, which can be chronic or non-chronic in origin. In some embodiments, the medical device comprises a drug depot that releases the ana (22) Filed: Apr. 25, 2011 bolic agent over at least 3 days to enhance wound healing. Patent Application Publication Oct. 25, 2012 US 2012/0271275 A1 o?uaegsås?on,ang?eoongoasoonaoºn6unee?-,punoanseneuerreoov?orozouens 2%3%%*{{{3% (siti) are e assad US 2012/0271275 A1 Oct. 25, 2012 MEDICAL DEVICES AND METHODS tions in the A, B, C and/or D rings have been made to increase COMPRISING AN ANABOLICAGENT FOR binding activity to the Steroid receptor and to increase lipid WOUND HEALING solubility of the anabolic steroids and prolong its activity. For example, alkylation at 17-alpha position with methyl or ethyl BACKGROUND groups create orally active compounds because it slows the 0001 Wounds can occur from various types of cuts, abra degradation of the drug by the liver.
    [Show full text]
  • Product List
    PRODUCT LIST Active Pharma Ingredients API Acid Reflux Disorders Product Pharmacopoeia CAS No. Technical Document A Acotiamide Hydrochloride - 773092-05-0 - Almagate EP 66827-12-1 - Aluminum Hydroxide BP, USP 21645-51-2 - C Cimetidine - 51481-61-9 - D Dexlansoprazole - 138530-94-6 - Dexlansoprazole - 313640-86-7 DMF Sesquihydrate Dexrabeprazole Sodium - 171440-18-9 ODMF, Tech Pack E Ecabet Sodium - 86408-72-2 DMF Esomeprazole - 119141-88-7 - Esomeprazole Magneisum - 217087-10-0 - Dihydrate Esomeprazole Magnesium - 161973-10-0 - Esomeprazole Magnesium USP 217087-09-7 CEP, DMF Trihydrate Esomeprazole Potassium IHS 161796-84-5 DMF Esomeprazole Sodium - 161796-78-7 - Esomeprazole Zinc/ 793668-08-3, - - Base/Strontium 119141-88-7 F Famotidine - 76824-35-6 - E Glycopyrrolate - 596-51-0 - H Hydrotelcite BP 12304-65-3 - I Ilaprazole IHS, IP 172152-36-2 DMF Ilaprazole Sodium - 172152-50-0 ODMF, Tech Pack Itopride - 122898-67-3 - Itopride Hydrochloride IHS 122892-31-3 - Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 1 API Acid Reflux Disorders Product Pharmacopoeia CAS No. Technical Document L Lafutidine - 118288-08-7 - Lansoprazole - 103577-45-3 - Lansoprazole Sodium - 226904-00-3 - M Magaldrate USP 74978-16-8
    [Show full text]
  • Anabolic Androgenic Steroids and Doping in Sport
    Medicina Sportiva (2013), vol. IX, no 1, 2009-2020 Romanian Sports Medicine Society 2009 Anabolic androgenic steroids and doping in sport Filomena Mazzeo, Antonio Ascione Department of Institutional and Territorial Systems Studies, University Parthenope, Naples, Italy Abstract. Anabolic steroids, technically known as anabolic-androgenic steroids (AAS), are synthetic derivatives of testosterone, modified to enhance its anabolic actions (promotion of protein synthesis and muscle growth). They are used by athletes (weightlifters, shot, hammer, discus or javelin throwers, rugby and American football players, swimmers and runners) to increase muscular mass and athletic performance and by bodybuilders to improve size and cosmetic appearance. AAS were the first identified doping agents that have ergogenic effects and are on the International Olympic Committee’s list of banned substances. The most popular AS used as doping substances are: oximetolone, oxandrolone, testosterone undecanoate, nandrolone decanoate, nandrolone undercanoate, methandrostenolone. To reach high dosages and rapid effects, steroid users practice a method known as “staking” which consist in the intake of two or more steroids in high dosages. Another method, called “pyramiding” provides a progressive increase of steroids dosage. The pyramid protocol is alternated with drug-free, process defined as “cycle”. AAS abuse causes significant side effect: infertility, azoospermia, testicular atrophy, and gynecomastia in men and in women may develop excessive body hair growth, menstrual irregularity, hypertrophy of sebaceous glands, acne. Other side effects are: premature cease of growth caused by premature epiphysis closure; Alteration of cardiovascular function; increase of platelet aggregation and plasmatic levels of low density lipoproteins (LDL); liver damage; euphoria, aggressiveness and psychosis. Their action in central neuron system involves the dopaminergic neurotransmission and produces amphetamine-like activity.
    [Show full text]